Anti-Spike-RBD-human-mAb(IgM) |
E24AHA005 |
EnoGene |
Humanized-Monoclonal-Antibody.human-IgM |
EUR 416.5 |
Description: Humanized Monoclonal Antibody.human IgM |
Human IgG antibody Laboratories manufactures the eenzyme mouse igm antibody to rbd-spike reagents distributed by Genprice. The Eenzyme Mouse Igm Antibody To Rbd-Spike reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact mouse Antibody. Other Eenzyme products are available in stock. Specificity: Eenzyme Category: Mouse Group: Igm Antibody
SARS-CoV-2 Spike RBD Protein IgG Antibody ELISA Kit |
Abclonal |
96T |
EUR 280 |
GENLISA Human Anti-SARS-CoV-2 IgG Antibody to Spike RBD Protein ELISA (Quantitative) - CE MARKED |
Krishgen |
1 x 96 wells |
EUR 379.5 |
GENLISA Rat Anti-SARS-CoV-2 IgG Antibody to Spike RBD protein Quantitative TITRATION ELISA |
Krishgen |
1 x 96 wells |
EUR 550 |
GENLISA Rabbit Anti-SARS-CoV-2 IgG Antibody to Spike RBD protein Quantitative TITRATION ELISA |
Krishgen |
1 x 96 wells |
EUR 550 |
GENLISA Equine Anti-SARS-CoV-2 IgG Antibody to spike protein RBD Quantitative TITRATION ELISA |
Krishgen |
1 x 96 wells |
EUR 550 |
Anti-Spike-RBD-Antibody(R15-F7) |
EnoGene |
N/A |
EUR 157.5 |
Description: N/A |
SARS-CoV-2-Spike-RBD-Antibody |
EnoGene |
N/A |
EUR 346.5 |
Description: N/A |
Igm Antibody information
anti-SARS-CoV-2 spike RBD VHH antibody |
JOT0007-1-50 |
Jotbody |
50 |
EUR 89.54 |
Description: Primary VHH single domain antibody |
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
9087-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
9087-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (AS113) (Omicron Specific) |
SPD-M305 |
ACROBIOSYSTEMS |
100ug |
EUR 5927.8 |
|
Description: The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Spike RBD. The antibody is specific against the Omicron (B.1.1.529/BA.1) variant of SARS-CoV-2, and has no binding with the spike RBD of the wild type virus and other viral lineages. |
SARS-CoV-2 Spike RBD protein antibody pair 1 |
CSB-EAP33245 |
Cusabio |
1 pair |
EUR 900 |
|
Description: This is a set of capture antibody and HRP-conjugated antbody for quantitative detection of SARS-CoV-2 Spike RBD protein for through solid phase sandwich ELISA. |
Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (AS106) (Beta & Gamma Specific) |
SPD-M416 |
ACROBIOSYSTEMS |
100ug |
EUR 5703.1 |
|
Description: The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Spike RBD. The antibody is specific against the Beta (B.1.351) and Gamma (P.1) variant of SARS-CoV-2, and has no binding with the spike RBD of the wild type virus, the Alpha (B.1.1.7) variant, the Delta (B.1.617.2) variant and the Omicron (B.1.1.529, BA.2) variant. |
SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin) |
9087-biotin-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin) |
9087-biotin-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
Anti-SARS-CoV-2 Spike RBD Broadly Antibody, Mouse IgG1 (2G7F5) (MALS verified) |
SPD-Y68 |
ACROBIOSYSTEMS |
100ug |
EUR 2493.1 |
|
Description: Anti-SARS-CoV-2 Spike RBD Broadly Antibody, Mouse IgG1 Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Spike protein. |
Mouse monoclonal Anti-MERS Spike protein RBD (MES-RBD) IgG1 (neutralizing) |
MERS125-M |
Alpha Diagnostics |
100 ul |
EUR 578.4 |
Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (9A6A11) (XBB.1.5/Omicron Specific) |
SPD-Y168 |
ACROBIOSYSTEMS |
1mg |
EUR 374.5 |
|
Description: It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (5C5C10) (BQ.1.1/Omicron Specific) |
SPD-Y170 |
ACROBIOSYSTEMS |
1mg |
EUR 374.5 |
|
Description: It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (5F8E1) (XBB.1.5/Omicron Specific) |
SPD-Y171 |
ACROBIOSYSTEMS |
1mg |
EUR 374.5 |
|
Description: It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B5] |
SD9431-002mg |
ProSci |
0.02 mg |
EUR 253.22 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B5] |
SD9431-01mg |
ProSci |
0.1 mg |
EUR 723.62 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B7] |
SD9433-002mg |
ProSci |
0.02 mg |
EUR 253.22 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B7] |
SD9433-01mg |
ProSci |
0.1 mg |
EUR 723.62 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |